BioNexus Gene Lab Corp Common stock (BGLC) — Free Cash Flow Generation Index

Latest as of December 2022: 0.96x

BioNexus Gene Lab Corp Common stock (BGLC) has a Free Cash Flow Generation Index of 0.96x as of December 2022. Free cash flow of $457.44K represents 1% of operating cash flow ($474.47K). Explore BioNexus Gene Lab Corp Common stock capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

0.96x
Free Cash Flow / Operating CF

Free Cash Flow

$457.44K
USD

Operating Cash Flow

$474.47K
USD

Capital Expenditures

$17.03K
USD

BioNexus Gene Lab Corp Common stock Free Cash Flow Generation Index (2017–2022)

Historical FCF Generation Index trend for BioNexus Gene Lab Corp Common stock across 4 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of BioNexus Gene Lab Corp Common stock.

Annual Free Cash Flow Generation for BioNexus Gene Lab Corp Common stock (2017–2022)

Year-by-year Free Cash Flow Generation Index for BioNexus Gene Lab Corp Common stock. Check BGLC cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2022 0.90x $489.86K $544.03K $54.17K ▲ +37.5%
2021 0.65x $6.00K $9.16K $3.16K ▲ +176.1%
2020 0.24x $131.06K $552.68K $421.62K ▲ +99.8%
2017 0.12x $42.40K $357.22K $314.82K
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).